NCT00410553: Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery |
|
|
| Completed | 1 | 45 | Canada | Eribulin Mesylate, B1939 Mesylate, E7389, ER-086526, Halaven, Halichondrin B Analog, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemzar, LY-188011, LY188011 | National Cancer Institute (NCI) | Adult Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Uterine Corpus Cancer AJCC v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Uterine Corpus Cancer AJCC v7 | 10/12 | 10/12 | | |
NCT02014337: Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors |
|
|
| Completed | 1 | 37 | US | Mifepristone and Eribulin in combination, Korlym®, Halaven | Corcept Therapeutics | Breast Cancer, Ovarian Epithelial Cancer Recurrent, Sarcoma, Non-small Cell Lung Cancer, Carcinoma, Transitional Cell, Prostate Cancer, Prostatic Neoplasms | 12/17 | 12/17 | | |
